ST segment elevation acute myocardial infarction in patients undergoing percutaneous coronary intervention

Active Ingredient: Clopidogrel

Indication for Clopidogrel

Population group: only adults (18 years old or older)

Therapeutic intent: Preventive action

ST segment elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent placement).

For this indication, competent medicine agencies globally authorize below treatments:

600 or 300 mg loading dose and thereafter 75 mg once daily

For:

Dosage regimens

Regimen A

Oral, 600 milligrams clopidogrel, one dose, over the duration of 1 day. Afterwards, oral, 75 milligrams clopidogrel, once daily.

Regimen B

Oral, 300 milligrams clopidogrel, one dose, over the duration of 1 day. Afterwards, oral, 75 milligrams clopidogrel, once daily.

Detailed description

When percutaneous coronary intervention (PCI) is intended:

Clopidogrel should be initiated at a loading dose of 600 mg in patients undergoing primary PCI and in patients undergoing PCI more than 24 hours of receiving fibrinolytic therapy. In patients ≥75 years old the 600 mg LD should be administered with caution.
Clopidogrel 300 mg loading dose should be given in patients undergoing PCI within 24 hours of receiving fibrinolytic therapy.

Clopidogrel treatment should be continued at 75 mg once a day with ASA 75 mg – 100 mg daily. Combined therapy should be started as early as possible after symptoms start and continued up to 12 months.

If a dose is missed:

Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time.
For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose.

Active ingredient

Clopidogrel
Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation. Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. Read more about Clopidogrel

Related medicines

Summary of Product Characteristics (SPC) 2024: ISCOVER Film-coated tablet

Structured Product Labeling (SPL/PLR) 2020: PLAVIX Film-coated tablet

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.